216 related articles for article (PubMed ID: 21737712)
1. FDA. Once on 'fast track,' avastin now derailed.
Couzin-Frankel J; Ogale Y
Science; 2011 Jul; 333(6039):143-4. PubMed ID: 21737712
[No Abstract] [Full Text] [Related]
2. Avastin hearing leads to more uncertainty over drug's future.
Goozner M
J Natl Cancer Inst; 2011 Aug; 103(15):1148-50. PubMed ID: 21768534
[No Abstract] [Full Text] [Related]
3. Thumbs up for Avastin.
Spalding BJ
Nat Biotechnol; 2008 Apr; 26(4):365. PubMed ID: 18392003
[No Abstract] [Full Text] [Related]
4. StatBite: Avastin Quarterly Sales, 2009-2011.
J Natl Cancer Inst; 2011 Aug; 103(15):1149. PubMed ID: 21768533
[No Abstract] [Full Text] [Related]
5. Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.
Schmucker C; Antes G; Lelgemann M
Surv Ophthalmol; 2009; 54(6):705-7. PubMed ID: 19818262
[No Abstract] [Full Text] [Related]
6. FDA and Avastin: crossroads in an era of targeted therapies.
Tripathy D
Oncology (Williston Park); 2010 Oct; 24(11):989-90. PubMed ID: 21155445
[No Abstract] [Full Text] [Related]
7. Changing end points in breast-cancer drug approval--the Avastin story.
D'Agostino RB
N Engl J Med; 2011 Jul; 365(2):e2. PubMed ID: 21707384
[No Abstract] [Full Text] [Related]
8. FDA panel votes to pull Avastin in breast cancer, again.
Ratner M
Nat Biotechnol; 2011 Aug; 29(8):676. PubMed ID: 21822226
[No Abstract] [Full Text] [Related]
9. Avastin, ODAC, and the FDA: are we drafting the right players?
Burstein HJ
J Natl Compr Canc Netw; 2010 Aug; 8(8):833-4. PubMed ID: 20870630
[No Abstract] [Full Text] [Related]
10. Bevacizumab (Avastin) for metastic breast cancer.
Med Lett Drugs Ther; 2008 Jun; 50(1287):42-3. PubMed ID: 18509265
[No Abstract] [Full Text] [Related]
11. Avastin's uncertain future in breast cancer treatment.
Twombly R
J Natl Cancer Inst; 2011 Mar; 103(6):458-60. PubMed ID: 21393607
[No Abstract] [Full Text] [Related]
12. FDA pulls approval for avastin in breast cancer.
Rose S
Cancer Discov; 2011 Dec; 1(7):OF1-2. PubMed ID: 22586694
[TBL] [Abstract][Full Text] [Related]
13. Reputation and precedent in the bevacizumab decision.
Carpenter D; Kesselheim AS; Joffe S
N Engl J Med; 2011 Jul; 365(2):e3. PubMed ID: 21707383
[No Abstract] [Full Text] [Related]
14. FDA cancels approval for bevacizumab in advanced breast cancer.
Tanne JH
BMJ; 2011 Nov; 343():d7684. PubMed ID: 22121166
[No Abstract] [Full Text] [Related]
15. Bevacizumab: improved survival at what cost?
Kolesar JM
Am J Health Syst Pharm; 2005 May; 62(10):1017. PubMed ID: 15901584
[No Abstract] [Full Text] [Related]
16. Avastin saga reveals debate over clinical trial endpoints.
Sharma SP
J Natl Cancer Inst; 2012 Jun; 104(11):800-1. PubMed ID: 22673590
[No Abstract] [Full Text] [Related]
17. Pushing the envelope.
Nat Biotechnol; 2011 Aug; 29(8):669. PubMed ID: 21822220
[No Abstract] [Full Text] [Related]
18. Biologics debate heats up between FDA, NCCN.
Carroll J
Manag Care; 2011 Sep; 20(9):30-2. PubMed ID: 21991859
[No Abstract] [Full Text] [Related]
19. Avastin withdrawal symptoms.
Lynce F; Swain SM
Expert Opin Pharmacother; 2012 Feb; 13(3):293-8. PubMed ID: 22263961
[No Abstract] [Full Text] [Related]
20. [The role of avastin in the treatment of breast carcinoma in Europe and the United States].
Rajnohová H; Nový F
Klin Onkol; 2011; 24(1):56. PubMed ID: 21542278
[No Abstract] [Full Text] [Related]
[Next] [New Search]
